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See Article, pages 1336–1342Transarterial chemoembolisation (TACE) delivers a chemothera-
peutic agent (usually doxorubicin) into the feeding vessels of a
hepatocellular carcinoma (HCC) and blocks the subsequent perfu-
sion of these vessels by the injection of a plugging material. Two
randomized controlled trials, conducted 10 years ago, reported a
survival advantage for patients with a preserved liver function
[1,2]. Subsequent meta-analysis conﬁrmed that TACE increased
the survival of patients with HCC [3,4]. TACE is a particularly
attractive option for the management of patients with HCC
because it is associated with few side effects and requires no
more than a 24-h hospitalization. Until recently, TACE was a
notoriously heterogeneous procedure with variable outcomes.
The demonstration that the delivery of small beads loaded with
doxorubicin was associated with fewer systemic side effects led
to a standardization of the TACE procedure [5]. TACE is offered
to patients in stage B of the Barcelona classiﬁcation, which repre-
sents the largest fraction of patients seeking treatment. There-
fore, improvements of TACE therapy are a matter of urgency.
TACE has two intrinsic limitations: it treats only the tumor tis-
sue dependent on the embolized vessels and it elicits a reaction
of growth factors. HCC sustains its growth by angiogenesis; spe-
ciﬁcally by promoting the formation of blood vessels from sur-
rounding arteries. Although TACE embolizes the principal
feeding arteries of the tumor, it leaves smaller vessels open,
which explains why the procedure is palliative and not curative.
Moreover, in cases of multifocal HCC with foci too small to be
radiologically visible, TACE does not treat these additional
lesions. In fact, it may even promote their growth [6]. Therefore,
one improvement would be to prevent the recruitment of these
secondary vessels. TACE induces a central anoxia with a periphe-
ral hypoxia. This hypoxic stress provokes cells to release angio-
genic growth factors. It is well documented that the circulating
levels of VEGF increase after TACE [7,8]. Nowadays these limita-
tions of TACE can be alleviated. Systemic antiangiogenic thera-
pies have been developed, exempliﬁed by sorafenib, which has
been approved for the systemic treatment of HCC. Although
attractive in theory, the combination of sorafenib with TACE
could be associated with more side effects, such as abscesses. AJournal of Hepatology 20
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sorafenib with TACE, beginning the systemic treatment a week
before the ﬁrst TACE and without stopping the drug during the
TACE sessions [9]. This study was not associated with major side
effects opening the ﬁeld to phase II studies.
In this issue of the Journal, Joong-Won Park and co-workers
report the results of a single-center phase II, open-label, single-
arm study combining sorafenib with TACE in 50 patients [10].
Ninety-four percent were Child–Pugh class A, 70% were treated
with surgical or locoregional therapies before enrollment. Sixty
percent received the concurrent treatment as planned for
24 weeks. The most common reasons for discontinuation of
sorafenib was HCC progression (17 patients), and for only 1
patient, adverse event. The authors report an overall median time
to progression of 7.3 months for the 41 patients BCLC stage B and
of 5.0 months for the 9 patients in BCLC stage C. The 6-month
progression-free survival rate was 52%. The authors conclude that
the increased survival is an improvement when compared with
historical control patients treated only with TACE. Given the het-
erogeneous characteristics of the patients included and of the his-
torical control population, it remains impossible to infer that the
combined treatment from this trial is more efﬁcacious. Moreover,
this trial was designed such that the systemic therapy with
sorafenib was withheld for the TACE sessions and reintroduced
on day 3 after the procedure or delayed further in case of major
laboratory abnormalities. This prudent scheme was selected to
avoid an augmentation of post-TACE complications with sorafe-
nib. Nevertheless, it might have been deleterious because of
tumor rebound after sorafenib interruption, as has been observed
in animal models [11]. Moreover, the concentration of VEGF
peaks on the day following TACE [7]. Therefore, in contrast to a
continuous scheme, this scheme denies sorafenib at the time it
is the most needed [12].
Additional studies have tested sorafenib in combination with
TACE. Erhardt presented a trial with a similar, interrupted design,
but enrolled 45 treatment naive patients and performed lipiodo-
lization rather than embolization [13]. The overall survival was
20 months. Unfortunately, the lack of a control group limits the
interpretation of the survival, which is not beyond the expected
range for patients treated with TACE only. The clinical commu-
nity awaits the results of the ECOG E1208 phase III trial, which
has included a control group, to better appreciate the potential
and limitations of interrupted combination (NCT01004978).12 vol. 56 j 1224–1225
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Pawlik et al. recently published the ﬁndings of a study with 35
advanced HCC patients, most of them BCLC stage C, and continu-
ous administration of sorafenib [14]. They report disease control
in 95% of the patients using the Response Evaluation Criteria in
Solid Tumor (RECIST). The lack of a control groups renders inter-
pretation difﬁcult. The large phase II SPACE trial randomized 307
patients for sorafenib or placebo. Sorafenib was given continu-
ously and TACE was performed with drug-eluting beads. The
hazard ration for time to progression was 0.797 and reached
the predeﬁned statistical level [15]. Nevertheless, the effect was
modest, with a median time to progression of 169 days in the
sorafenib group vs. 166 days in the placebo group.
Taken together, these trials conﬁrm the phase I study showing
that the combination of sorafenib with TACE is associated with
manageable side effects. However, these results underline the
necessity to collect good quality clinical data on the combination
of systemic targeted therapy with TACE in order to design clinical
trials optimizing enrollment criteria and end points to capture
the magnitude of the effect. In particular, the transient perturba-
tion of the laboratory results occurring after TACE should be care-
fully integrated. Finally, if sorafenib has the advantage of proven
efﬁcacy in monotherapy, trials are testing the combination of
TACE with other antiangiogenic systemic therapies such as briv-
anib (NCT00908752) or everolimus (NCT01009801). In particular,
everolimus lowers circulating VEGF levels, in contrast to sorafe-
nib which increases them [16].Conﬂict of interest
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